alexa Risperidone Long-acting Injectable versus Paliperidone

Research & Reviews: Journal of Pharmaceutical Quality Assurance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Risperidone Long-acting Injectable versus Paliperidone Palmitate for Community-dwelling Patients with Schizophrenia

Amanda Webster1* and Shaun Phillips2

1Clinical Pharmacist, Bronson Battle Creek Hospital, Battle Creek, MI, 49015, USA

2AVP of Diagnostic and Therapy Services, Pharmacy Residency Program Director, Bronson Battle Creek Hospital, Adjunct Professor of Clinical Pharmacy/Administration, Ferris State University, Battle Creek, MI, 49015, USA

*Corresponding Author:
Amanda Webster
Clinical Pharmacist, Bronson Battle Creek Hospital
Battle Creek, MI, 49015, USA
Tel: (269) 245-5987
Fax: (269) 245-5987
E-mail: [email protected]

Received date: 07/10/2015; Accepted date: 17/10/2015; Published date: 24/10/2015



Purpose: Studies indicate that poor medication compliance often hinders positive treatment outcomes in patients with schizophrenia. Risperidone long-acting injectable and paliperidone palmitate theoretically aid compliance as they are given only once every two or four weeks, respectively. Because the two formulations share similar pharmacologic and pharmacokinetic properties, further evaluation is required to determine whether clinically significant differences in patient outcome exist and the impact of these variations. The purpose of this study was to determine whether community-dwelling patients with schizophrenia receiving risperidone longacting injectable incur improved clinical outcomes or lowered costs than patients receiving paliperidone palmitate.

Methods: A retrospective cohort chart review was conducted on patients who had an encounter at our institution while receiving risperidone long-acting injectable or paliperidone palmitate from January 1, 2011 to December 31, 2012. The primary objective of this study was to determine the total cost of psychiatric-related care for patients receiving paliperidone palmitate versus risperidone long‑acting injectable. Secondary objectives included comparisons of hospitalization days and emergency department encounters in patient-days, time to discontinuation, and time to first relapse. A subgroup analysis was conducted on patients receiving injections through a local ambulatory psychiatric facility.

Results: A total of 47 patients were included in the primary analysis with 30 patients included in the ambulatory psychiatric subgroup analysis. Risperidone long-acting injectable patients incurred lower psychiatryrelated treatment costs per patient-day than paliperidone palmitate under the total (p=0.032) and ambulatory psychiatric subgroup (p=0.049) analyses. Ambulatory psychiatric risperidone long-acting injectable patients were found to require fewer psychiatric inpatient days (p=0.044) than paliperidone palmitate patients.

Conclusion: Use of risperidone long-acting injectable was associated with significantly fewer psychiatric inpatient days and lower psychiatryrelated costs than paliperidone palmitate in our population of communitydwelling patients with schizophrenia.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version